Hematologists Global Summit July 13-14, 2018 Sydney, Australia

Dr. Nasha Winters, ND, LAc, DiplOM, FABNO, is the founder, CEO, and visionary of Optimal Terrain Consulting. She has been working in the health care industry for over 25 years and is a national board certified Naturopathic Doctor (ND), licensed Acupuncturist (L.Ac), practitioner of Oriental Medicine (DiplOM), and a Fellow of the American Board of Naturopathic Oncology (FABNO). Dr. Winters is globally recognized as co-authoring the best selling book The Metabolic Approach to Cancer, and she is currently co-authoring (working title) Advances in Mistletoe Therapy: Global Perspectives on Integrating Mistletoe as an Adjunct Therapy with Cancer, Auto-Immunity, Infectious Diseases, Endocrine Disorders, and More. Dr. Winters was instrumental in the development of the Johns Hopkins Viscum Album research trial and continues to lend expertise to their investigation team.

She is a frequent key note speaker at conferences and lectures all over the world and was recently selected by the 2018 International Medical Meeting’s Scientific and Medical Committee as their keynote speaker in Germany. Dr. Winters trains doctors in mistletoe therapy and is the foremost expert in the metabolic and cancer relationship. She developed the Terrain Ten integrative medical methodology and consults with researchers on projects involving immune modulation via mistletoe, hyperthermia, and the ketogenic diet.

Mr. Deven Patel, the CEO, President and Cofounder of Global Institute of Stem Cell Therapy and Research (GIOSTAR) with headquarter in San Diego, California, U.S.A. GIOSTAR was formed with the vision to provide affordable stem cell based therapies to the masses around the world suffering from degenerative or genetic diseases and unable to afford today’s high cost of the treatment. He was honored with USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the world. He was also bestowed upon Asian Heritage Award for his business leadership in the field of stem cell science. GIOSTAR under the leadership of Mr. Patel is in charge of developing stem cell transplant program for four different State Governments in India with total population of approx. 155 million. GIOSTAR, in collaborations with Government of Gujarat, India, world's largest state of the art Stem Cell Treatment Hospital in India. GIOSTAR is in process of developing its facility in China, Thailand, Colombia, Bahamas, Dubai and Austalia.

The Stem Cell Therapy and Its Emerging Markets

Dr Piyush Vyas is board certified clinical oncologist , presently persuing his next sub speciality training in clinical hematology.Being an academic teacher at Medical University of Warsaw, he is engaged in teaching oncology to undergradute and postgraduate students.Having had published reviews, research articles, case studies, poster presentations , Dr Piyush Vyas is well respected in academic circles of oncology . Dr Piyush Vyas is on editorial board / reviewer of many US and other international oncology/hematology/surgery journals. Dr Vyas is / was member of ASCO, ESMO, EHA, AACR, Polish Society of Clinical Oncology etc. as full member / associate member .Having had passed the most prestigious oncology exam the world over " European Society of Medical Oncology Exam" Dr Vyas has proved his world class clinical expertise / knowledge in managing oncology and haematological patients.Among others achievements.

Dr Piyush Vyas has credit to publish the first case study of a patient with metastatic duodenal carcinoma with concurrent immune thrombocytopenia treated with chemotherapy successfully, credit to publish a case study of a patient who seems to be longest survior( as per available literaturÄ™) with stage IV adenocarcinoma of lung treated with tyrosine kinase inhibitor -Erlotinib . Being innovative in his approach Dr Piyush Vyas offered an economically very cost effective method of treating hepatocellular cancers with chemotherapy protocol FOLFOX4, very much appreciated approach in third world countries where targeted therapies are not widely available by publishing his marvellous article on hepatocellular cancer. He has been invited as speaker/ keynote speaker for international conferences .His poster presentations had been widely appreciated and had been very informative.Dr Piyush Vyas among others lastly presented an e poster as first author at Polish Annual Conference of Hematologists and Transfusion Medicine specialists - 2017, organised at Warsaw,Poland , where his group proved that not every thrombocytopenia patient should be disqualified as many of them can be immune thrombocytopenias, which can be effectively be treated.He is fluent in 4 languages , thus has a large geographical audience which he covers writting his articles in Polish, English etc.. His main research interest is in solid tumours with concurrent immune thrombocytopenias, solid tumours and in haematological malignancies.

Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA.

His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc. He has participated at more than three hundreds reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Turkey, France, Swiss, Germany, Sweden, Norway, Italy, Austria, Czech Republic, Hungary, Poland, South Africa, Egypt, Brazil, Spain, Portugal, Mexico, Japan, Singapore, Malaysia, Thailand, Taiwan, Hong Kong, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than nine hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than three hundreds reputed international academic–scientific–research institutes around the world. It

Dr. Ashok Srivastava is Chief Executive Officer and Chief Medical Officer of Cure Pharmaceuticals, and ClinFomatrix Oncology, He was founder, Chief Executive Officer and Chief Medical Officer of CareBeyond - A Radiation Therapy Cancer Center, New Jersey, USA. He has more than 15 years of experience in drug development , medical affairs and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase I – 4, and marketing commercialization of Hematology, Oncology and radio-immuno-oncology drugs in USA , EU and Japan. He is leader in Cancer Drug Development Worldwide large and complex Phase 3 Clinical Trials. He contributed to 21-INDs and 7-NDAs of Cancer Drugs, acquisition /merger of company and drug for more than $300 million. He received his clinical, medical training & worked at renowned medical centers and pharmaceutical institutions worldwide; Walter Reed Army Institute of Research and Medical Center, Daiichi, Sumitomo, Pharmacia, Pfizer, Eisai Oncology, and Spectrum Pharmaceuticals. He received his Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India; Academy of Medical Sciences, Czechoslovakia; School of Medicine Nagasaki University, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He played key role in dramatic expansion of oncology drug – developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel for HER2 positive metastatic breast cancer patients and latuda (Lurasidone) for schizophrenia

He is one of the inventors of Japanese encephalitis vaccine (IXIARO) . He has published more than 85 papers in National and International Journals, more than 120 abstracts, 3 book chapters and 2 patents. He is recipient of numerous National & International prestigious medical awards and recognitions from United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington DC, USA. He served as medical advisor to Poniard Pharmaceutical for small cell lung cancer and Taiho Oncology in USA, EU and India. Dr. Srivastava is member of numerous prestigious organizations; America’s Top Oncologist of the years 2017, Breast Cancer Foundation , Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer. Dr. Srivastava is a strategic medical advisor and Board Member to several pharma in USA for clinical, regulatory and supervises cancer drug development . Recently Dr. Srivastava was awarded membership of Japan External Trade Organization, USA. Dr. Srivastava is a Leader in Drug Safety, pharmacovigilance of Oncology, hematology, immuno-oncology and built global drug safety and pharmacovigilance companies in USA, and India. Dr. Srivastava was invited as an honorable speaker at drug safety & Pharmacovigilance congress in London, UK, India and Washington, DC, USA in 2017. Dr. Srivastava brought 2 cancer drugs & a vaccine in global market for approx 3 – 3.5 billion $ global sales. He serves as board of director s for oncology pharma companies.